Estrogen-induced Pro-cathepsin D and its Relationship to Breast Cancer Invasion and Metastasis

[1]  H. Rochefort,et al.  Cathepsin D in breast cancer cells can digest extracellular matrix in large acidic vesicles. , 1990, Cancer research.

[2]  T. Maudelonde,et al.  Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. , 1990, European journal of cancer.

[3]  T. Maudelonde,et al.  CATHEPSIN D: AN INDEPENDENT PROGNOSTIC FACTOR FOR METASTASIS OF BREAST CANCER , 1989, The Lancet.

[4]  I. Christensen,et al.  Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. , 1989, Cancer research.

[5]  H. Rochefort,et al.  Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells. , 1989, Cancer research.

[6]  T. Maudelonde,et al.  Tamoxifen treatment increases the concentration of 52K‐cathepsin D and its precursor in breast cancer tissue , 1989, Cancer.

[7]  H. Rochefort,et al.  Regulation of cathepsin-D and pS2 gene expression by growth factors in MCF7 human breast cancer cells. , 1989, Molecular endocrinology.

[8]  H. Rochefort,et al.  Characterization and properties of two monoclonal antibodies specific for the Mr 52,000 precursor of cathepsin D in human breast cancer cells. , 1988, Cancer research.

[9]  H. Rochefort,et al.  In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells. , 1988, Cancer research.

[10]  H. Rochefort,et al.  Estrogens and growth factors induce the mRNA of the 52K-pro-cathepsin-D secreted by breast cancer cells. , 1988, Nucleic acids research.

[11]  M. Mattei,et al.  Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11. , 1988, Molecular endocrinology.

[12]  T. Maudelonde,et al.  Immunoenzymatic assay of Mr 52,000 cathepsin D in 182 breast cancer cytosols: low correlation with other prognostic parameters. , 1988, Cancer research.

[13]  W. Rutter,et al.  Insulin-like growth factor II receptor as a multifunctional binding protein , 1987, Nature.

[14]  Marcel Garcia,et al.  Estrogen‐induced lysosomal proteases secreted by breast cancer cells: A role in carcinogenesis? , 1987, Journal of cellular biochemistry.

[15]  F. May,et al.  Oestrogen regulates cathepsin D mRNA levels in oestrogen responsive human breast cancer cells. , 1987, Nucleic acids research.

[16]  A. Barrett,et al.  Phosphorylation, glycosylation, and proteolytic activity of the 52-kD estrogen-induced protein secreted by MCF7 cells , 1987, The Journal of cell biology.

[17]  H. Rochefort,et al.  Processing and estrogen regulation of the 52-kilodalton protein inside MCF7 breast cancer cells. , 1986, Endocrinology.

[18]  B. Pau,et al.  Distribution of the Mr 52,000 estrogen-regulated protein in benign breast diseases and other tissues by immunohistochemistry. , 1986, Cancer research.

[19]  H. Rochefort,et al.  Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. , 1986, Endocrinology.

[20]  M. Gottesman,et al.  The major excreted protein of transformed fibroblasts is an activable acid-protease. , 1986, The Journal of biological chemistry.

[21]  B. Pau,et al.  Characterization of monoclonal antibodies to the estrogen-regulated Mr 52,000 glycoprotein and their use in MCF7 cells. , 1985, Cancer research.

[22]  H. Dickerman,et al.  Estradiol preferentially enhances extracellular tissue plasminogen activators of MCF-7 breast cancer cells. , 1984, The Journal of biological chemistry.

[23]  A. Krust,et al.  Effects of antiestrogens on the estrogen-regulated pS2 RNA and the 52- and 160-kilodalton proteins in MCF7 cells and two tamoxifen-resistant sublines. , 1984, The Journal of biological chemistry.

[24]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[25]  K. von Figura,et al.  Lysosomal enzyme precursors in human fibroblasts. Activation of cathepsin D precursor in vitro and activity of beta-hexosaminidase A precursor towards ganglioside GM2. , 1982, European journal of biochemistry.

[26]  H. Rochefort,et al.  A secreted glycoprotein induced by estrogen in human breast cancer cell lines , 1980, Cell.

[27]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[28]  W. B. Butler,et al.  Induction of plasminogen activator by estrogen in a human breast cancer cell line (MCF-7). , 1979, Biochemical and biophysical research communications.

[29]  A. Barrett.  Cathepsin D. Purification of isoenzymes from human and chicken liver. , 1970, The Biochemical journal.

[30]  Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[31]  B. Pau,et al.  Two-site immunoenzymometric assay for the 52-kDa cathepsin D in cytosols of breast cancer tissues. , 1989, Clinical chemistry.

[32]  M. Duffy,et al.  Plasminogen activator, a new marker in breast cancer , 1987 .

[33]  M. García,et al.  Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. , 1987, Journal of steroid biochemistry.

[34]  R. Goldfarb.  Proteolytic Enzymes in Tumor Invasion and Degradation of Host Extracellular Matrices , 1986 .

[35]  K. von Figura,et al.  Lysosomal enzymes and their receptors. , 1986, Annual review of biochemistry.

[36]  R. Dickson,et al.  Induction of epidermal growth factor-related polypeptides by 17 beta-estradiol in MCF-7 human breast cancer cells. , 1986, Endocrinology.

[37]  P. Siekevitz,et al.  A Guided Tour of the Living Cell , 1984 .